Standout Papers

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for adv... 2021 2026 2022 2024188
  1. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ (2021)
    Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology

Immediate Impact

7 by Nobel laureates 4 from Science/Nature 55 standout
Sub-graph 1 of 24

Citing Papers

Natural killer cell therapies
2024 StandoutNature
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
3 intermediate papers

Works of Jane Healy being referenced

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
2020
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Jane Healy 318 263 111 192 24 744
Noelia Escobedo 402 260 39 148 18 772
Konrad Kölble 194 385 104 142 29 902
Barbara Ikejiri 228 371 77 179 27 890
Rebecca L. Porter 104 304 74 110 31 711
Sasidhar Vemula 131 466 92 153 27 932
Samia B. Bachmann 408 237 46 106 15 658
Akiko Arakawa 202 258 72 472 23 918
Daniel T. Sweet 307 310 129 71 13 721
Uwe Schlomann 306 464 78 93 28 937
René Hägerling 684 417 70 70 23 983

All Works

Loading papers...

Rankless by CCL
2026